Q2 FY2026 EarningsQ2 FY26 results beat consensus on both top and bottom lines: revenue $210.9M vs. $209.3M expected, and GAAP EPS $(0.39) vs. $(0.41) expected. Strong performance in Global Limb Reconstruction (+13% YoY) and Spine Fixation drove 5% constant currency growth, offsetting temporary reimbursement headwinds in Therapeutic Solutions. Management raised FY26 revenue guidance to $845M-$855M and Adjusted EBITDA to $95M-$98M, signaling confidence in operational transformation and the restoration of Medicare bone growth stimulator coverage.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Orthofix(OFIX) the Revenue is 210.93 M (+3.85%), Beat estimate;the EBIT is -8.134 M (+49.17%), Beat estimate;the EPS is -0.39 (-8.33%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.21B3.85%
0.21B3.03%
+0.00B0.82%
EBITExceed expectations
-0.01B49.17%
-0.01B20.86%
+0.00B28.31%
EPSExceed expectations
-0.398.33%
-0.4113.89%
+0.02005.56%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf